Urothelial Cancer CPG Mini Module - Management of High-Risk Non-Muscle Invasive Bladder Cancer

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

Joshua Meeks, MD, PhD - Northwestern University, presents a case of high-risk, non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG) and pembrolizumab.  This presentation addresses treatment of NMIBC during a BCG shortage and the criteria for BCG unresponsiveness.  Results of the KEYNOTE-057 trial, which tested the efficacy of pembrolizumab for treating patients with NMIBC, are also presented.  This mini module closes with a panel discussion on additional factors that should be considered when treating patients who are unresponsive to BCG.

Run time: 9 minutes, 36 seconds

Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021). 
 
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.